Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial

Fatemeh Ayoobi, Amir Moghadam-Ahmadi, Houshang Amiri, Alireza Vakilian, Moslem Heidari, Habib Farahmand, Mahmood Sheikh Fathollahi, Iman Fatemi, Seyed Ali Shafiei, Mohammad Alahtavakoli, Ali Shamsizadeh

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Multiple sclerosis (MS) is a neurological disease for which to date there is no cure and the existing disease-modifying drugs just slow down the disease progression. Purpose: In this clinical trial we evaluated the efficacy of Achillea millefolium (A. millefolium) aqueous extract in MS patients. Methods: A triple-blind randomized placebo-controlled parallel group trial was conducted on 75 MS patients. The patients were randomized into three groups including placebo and two groups receiving A. millefolium with two different doses, i.e. 250 mg/day and 500 mg/day, for 1 year. The primary outcome was the annualized relapse rate. Also, number and volume of lesions were obtained from magnetic resonance imaging (MRI) scans. Furthermore, we performed a comprehensive neurological and cognitive tests as follows: changes in the expanded disability status scale (EDSS), the multiple sclerosis functional composite (MSFC), fatigue severity scale (FSS), Ashworth spasticity assessment, Beck depression test, State-trait anxiety inventory (STAI), mini-mental status examination (MMSE), Wisconsin card sorting test (WCST), tower of London test (TOL), word-pair learning, paced auditory serial addition task (PASAT) and standard laboratory tests. Results: This study showed one year administration of A. millefolium (both doses) decreased the annual relapse rate in MS patients. The mean volume change of lesions significantly decreased in the 500 mg A. millefolium group. The add-on therapy also increased time to first relapse and the MSFC z-score; it decreased the EDSS score and improved performance in word-pair learning, PASAT, and WCST. Conclusion: We found beneficial effects of A. millefolium aqueous extract as an add-on therapy in MS patients.
LanguageEnglish
Pages89-97
JournalPhytomedicine
Volume52
DOIs
StatePublished - 2019

Cite this

Ayoobi, F., Moghadam-Ahmadi, A., Amiri, H., Vakilian, A., Heidari, M., Farahmand, H., ... Shamsizadeh, A. (2019). Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial. Phytomedicine, 52, 89-97. DOI: 10.1016/j.phymed.2018.06.017
Ayoobi, Fatemeh ; Moghadam-Ahmadi, Amir ; Amiri, Houshang ; Vakilian, Alireza ; Heidari, Moslem ; Farahmand, Habib ; Fathollahi, Mahmood Sheikh ; Fatemi, Iman ; Shafiei, Seyed Ali ; Alahtavakoli, Mohammad ; Shamsizadeh, Ali. / Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial. In: Phytomedicine. 2019 ; Vol. 52. pp. 89-97
@article{9c983869948d455bac9cb52ef47be359,
title = "Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial",
abstract = "Background: Multiple sclerosis (MS) is a neurological disease for which to date there is no cure and the existing disease-modifying drugs just slow down the disease progression. Purpose: In this clinical trial we evaluated the efficacy of Achillea millefolium (A. millefolium) aqueous extract in MS patients. Methods: A triple-blind randomized placebo-controlled parallel group trial was conducted on 75 MS patients. The patients were randomized into three groups including placebo and two groups receiving A. millefolium with two different doses, i.e. 250 mg/day and 500 mg/day, for 1 year. The primary outcome was the annualized relapse rate. Also, number and volume of lesions were obtained from magnetic resonance imaging (MRI) scans. Furthermore, we performed a comprehensive neurological and cognitive tests as follows: changes in the expanded disability status scale (EDSS), the multiple sclerosis functional composite (MSFC), fatigue severity scale (FSS), Ashworth spasticity assessment, Beck depression test, State-trait anxiety inventory (STAI), mini-mental status examination (MMSE), Wisconsin card sorting test (WCST), tower of London test (TOL), word-pair learning, paced auditory serial addition task (PASAT) and standard laboratory tests. Results: This study showed one year administration of A. millefolium (both doses) decreased the annual relapse rate in MS patients. The mean volume change of lesions significantly decreased in the 500 mg A. millefolium group. The add-on therapy also increased time to first relapse and the MSFC z-score; it decreased the EDSS score and improved performance in word-pair learning, PASAT, and WCST. Conclusion: We found beneficial effects of A. millefolium aqueous extract as an add-on therapy in MS patients.",
author = "Fatemeh Ayoobi and Amir Moghadam-Ahmadi and Houshang Amiri and Alireza Vakilian and Moslem Heidari and Habib Farahmand and Fathollahi, {Mahmood Sheikh} and Iman Fatemi and Shafiei, {Seyed Ali} and Mohammad Alahtavakoli and Ali Shamsizadeh",
year = "2019",
doi = "10.1016/j.phymed.2018.06.017",
language = "English",
volume = "52",
pages = "89--97",
journal = "Phytomedicine",
issn = "0944-7113",

}

Ayoobi, F, Moghadam-Ahmadi, A, Amiri, H, Vakilian, A, Heidari, M, Farahmand, H, Fathollahi, MS, Fatemi, I, Shafiei, SA, Alahtavakoli, M & Shamsizadeh, A 2019, 'Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial' Phytomedicine, vol. 52, pp. 89-97. DOI: 10.1016/j.phymed.2018.06.017

Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial. / Ayoobi, Fatemeh; Moghadam-Ahmadi, Amir; Amiri, Houshang; Vakilian, Alireza; Heidari, Moslem; Farahmand, Habib; Fathollahi, Mahmood Sheikh; Fatemi, Iman; Shafiei, Seyed Ali; Alahtavakoli, Mohammad; Shamsizadeh, Ali.

In: Phytomedicine, Vol. 52, 2019, p. 89-97.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial

AU - Ayoobi,Fatemeh

AU - Moghadam-Ahmadi,Amir

AU - Amiri,Houshang

AU - Vakilian,Alireza

AU - Heidari,Moslem

AU - Farahmand,Habib

AU - Fathollahi,Mahmood Sheikh

AU - Fatemi,Iman

AU - Shafiei,Seyed Ali

AU - Alahtavakoli,Mohammad

AU - Shamsizadeh,Ali

PY - 2019

Y1 - 2019

N2 - Background: Multiple sclerosis (MS) is a neurological disease for which to date there is no cure and the existing disease-modifying drugs just slow down the disease progression. Purpose: In this clinical trial we evaluated the efficacy of Achillea millefolium (A. millefolium) aqueous extract in MS patients. Methods: A triple-blind randomized placebo-controlled parallel group trial was conducted on 75 MS patients. The patients were randomized into three groups including placebo and two groups receiving A. millefolium with two different doses, i.e. 250 mg/day and 500 mg/day, for 1 year. The primary outcome was the annualized relapse rate. Also, number and volume of lesions were obtained from magnetic resonance imaging (MRI) scans. Furthermore, we performed a comprehensive neurological and cognitive tests as follows: changes in the expanded disability status scale (EDSS), the multiple sclerosis functional composite (MSFC), fatigue severity scale (FSS), Ashworth spasticity assessment, Beck depression test, State-trait anxiety inventory (STAI), mini-mental status examination (MMSE), Wisconsin card sorting test (WCST), tower of London test (TOL), word-pair learning, paced auditory serial addition task (PASAT) and standard laboratory tests. Results: This study showed one year administration of A. millefolium (both doses) decreased the annual relapse rate in MS patients. The mean volume change of lesions significantly decreased in the 500 mg A. millefolium group. The add-on therapy also increased time to first relapse and the MSFC z-score; it decreased the EDSS score and improved performance in word-pair learning, PASAT, and WCST. Conclusion: We found beneficial effects of A. millefolium aqueous extract as an add-on therapy in MS patients.

AB - Background: Multiple sclerosis (MS) is a neurological disease for which to date there is no cure and the existing disease-modifying drugs just slow down the disease progression. Purpose: In this clinical trial we evaluated the efficacy of Achillea millefolium (A. millefolium) aqueous extract in MS patients. Methods: A triple-blind randomized placebo-controlled parallel group trial was conducted on 75 MS patients. The patients were randomized into three groups including placebo and two groups receiving A. millefolium with two different doses, i.e. 250 mg/day and 500 mg/day, for 1 year. The primary outcome was the annualized relapse rate. Also, number and volume of lesions were obtained from magnetic resonance imaging (MRI) scans. Furthermore, we performed a comprehensive neurological and cognitive tests as follows: changes in the expanded disability status scale (EDSS), the multiple sclerosis functional composite (MSFC), fatigue severity scale (FSS), Ashworth spasticity assessment, Beck depression test, State-trait anxiety inventory (STAI), mini-mental status examination (MMSE), Wisconsin card sorting test (WCST), tower of London test (TOL), word-pair learning, paced auditory serial addition task (PASAT) and standard laboratory tests. Results: This study showed one year administration of A. millefolium (both doses) decreased the annual relapse rate in MS patients. The mean volume change of lesions significantly decreased in the 500 mg A. millefolium group. The add-on therapy also increased time to first relapse and the MSFC z-score; it decreased the EDSS score and improved performance in word-pair learning, PASAT, and WCST. Conclusion: We found beneficial effects of A. millefolium aqueous extract as an add-on therapy in MS patients.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055691645&origin=inward

U2 - 10.1016/j.phymed.2018.06.017

DO - 10.1016/j.phymed.2018.06.017

M3 - Article

VL - 52

SP - 89

EP - 97

JO - Phytomedicine

T2 - Phytomedicine

JF - Phytomedicine

SN - 0944-7113

ER -

Ayoobi F, Moghadam-Ahmadi A, Amiri H, Vakilian A, Heidari M, Farahmand H et al. Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial. Phytomedicine. 2019;52:89-97. Available from, DOI: 10.1016/j.phymed.2018.06.017